Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $108
Portfolio Pulse from Benzinga Newsdesk
Barrington Research has maintained its Outperform rating on Haemonetics (NYSE:HAE) and raised the price target from $107 to $108.
August 09, 2024 | 9:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barrington Research has maintained its Outperform rating on Haemonetics and raised the price target from $107 to $108.
The Outperform rating and slight increase in the price target from $107 to $108 by Barrington Research suggests a positive outlook for Haemonetics. This could lead to a short-term increase in the stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100